anticancer agent
Sponsors
Fukuoka University Hospital, iTeos Belgium SA
Conditions
Patients with recurrent ovarian cancerSelected Advanced Solid Tumors
Phase 1
Phase I study in the continual administration of BK-UM against HB-EGF for patients with advanced or recurrent ovarian cancer
Active, not recruitingJPRN-UMIN000001001
Start: 2008-02-01Target: 24Updated: 2026-06-29
A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors
TerminatedNCT06877533
Start: 2025-04-07End: 2025-07-10Updated: 2025-08-12